Featured Program
Featured Resources
Featured Advocacy Letters
NCL Sends Letter to Senate HELP Committee on Lowering Healthcare Costs
/in Featured Home - Health/by allisoncAugust 1, 2025: Washington, DC – On July 31, 2025, the Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing on the rising cost of healthcare and the urgent need for patient-focused reform. Lawmakers and expert witnesses discussed challenges with employer-sponsored insurance, the lack of price transparency, and the profit-driven nature of the U.S. healthcare system.
Featured Press Releases
Lower Prices, Real Savings: Competition Is Key at the Pharmacy Counter
/in Featured Home - Health/by Lisa McDonaldWashington, DC — The National Consumers League (NCL) today welcomed the Senate HELP Committee’s hearing on generics and biosimilars as an important bipartisan step toward lowering prescription drug costs through increased competition.
Verdict Opens the Door to Lower Prices, Transparency, and Real Competition
/in Featured Home - Consumer Protection/by allisoncApril 15, 2026: Washington, DC — “Today’s verdict confirms what millions of fans already knew: Live Nation and Ticketmaster used their dominance to build and protect an illegal monopoly at the direct expense of consumers,” said John Breyault, Vice President of Public Policy, Telecommunications, and Fraud at the National Consumers League.
National Consumers League Applauds Progress on Responsible GLP-1 Marketing
/in Featured Home - Food, Nutrition, & Obesity/by Lisa McDonaldMarch 9, 2026: Washington, DC – As an organization focused on the safety of GLP-1 weight-loss drugs, the National Consumers League welcomes the agreement between Novo Nordisk and the telehealth platform Hims & Hers as an important step that could turn the tide away from consumers opting for unapproved GLP-1 weight-loss products.
National Consumers League Commends FDA for Swift Action Against Hims & Hers
/in Featured Home - Food, Nutrition, & Obesity/by Lisa McDonaldFebruary 9, 2026: Washington, DC – You can fool some of the people some of the time and all of the people some of the time. But you can’t fool all of the people all the time. On Friday, February 6, the Food and Drug Administration announced it would stop the telehealth platform Hims & Hers from marketing a compounded version of the first FDA-approved GLP-1 weight-loss pill. On Saturday, Hims & Hers said it was withdrawing the product from the market, and the FDA did not pursue enforcement action.